RLFTF - Acer Therapeutics stock rises 10% on Chinese patent for urea cycle disorder therapy

• Acer Therapeutics ( NASDAQ: ACER ) is trading 10% higher after it said on Friday that the China National Intellectual Property Administration had issued electronic patent for its drug, ACER-001, to treat patients with urea cycle disorders, rare genetic conditions primarily diagnosed in children.
• The company said the newly issued patent has an expiration date of August 24, 2031.
• Relief Therapeutics ( OTCQB:RLFTF ) and Acer ( ACER ) have a development and commercialization agreement for ACER-001.
• "The issuance of this patent also marks an important step in our pursuit of possible ACER-001 commercialization in China," said Raghuram Selvaraju, Chairman of Relief.
• Last month , the U.S. Food and Drug Administration declined to approve the drug, ACER-001, stating that the agency's field investigator could not complete inspection of Acer’s third-party contract packaging manufacturer, because the facility was not ready for inspection.

For further details see: